I hesitated while pasting together this Bio-Twitter Year in Review because... Does anyone really want to remember what happened in 2016?

Don't all raise your hands at once; 2016 was a lousy year for biotech investors. It started bad, got worse, perked up, got worse again, rebounded just a little, looked like it was normalizing then tanked -- again.

Brutal. 

Still, if we have to look back at the pain, why not have some fun with it? I combed through my Twitter archive to compile a 2016 biotech review in tweets. Month by month, here's how 2016 went -- for you  and for me. 

January

You know a bad year is coming when your beloved dog dies right after New Year's Day. 

Max died today. We're heartbroken. Lover of tennis balls, water, mud & runs in woods. My best buddy. I miss him. ❤️ pic.twitter.com/o0wRekNdIe

— Adam Feuerstein (@adamfeuerstein) January 4, 2016

MannKind (MNKD) kaboom!

And on the second business day of 2016…$SNY ditches $MNKD

— Adam Feuerstein (@adamfeuerstein) January 5, 2016

Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference.

When you wake up at 3 am excited for lots of big, surprising #JPM16 Monday biotech news but instead get… pic.twitter.com/THDd05lgs8

— Adam Feuerstein (@adamfeuerstein) January 11, 2016

This! (Followed fast by the FDA's decision to postpone the Sarepta (SRPT) advisory panel.)

$SRPT — eteplirsen dystrophin production better than drisapersen but not saying much. 0.9% of normal. Yikes.

— Adam Feuerstein (@adamfeuerstein) January 15, 2016

Biotech stocks cratered...

@bradloncar pic.twitter.com/jv0QCQ5HTx

— Adam Feuerstein (@adamfeuerstein) January 22, 2016

By the end of January, there was nowhere for investors to hide...

. @bradloncar Sorta like this, Brad. pic.twitter.com/Ko36AJFIoP

— Adam Feuerstein (@adamfeuerstein) January 29, 2016

February

No, dumbass, four more years of Trump! 

Can someone please remind me. If Punxsutawney Phil sees his shadow tomorrow, does that mean six more weeks of Trump?

— Adam Feuerstein (@adamfeuerstein) February 1, 2016

And surely someone shouted, "Buy the Gilead (GILD) dip!" 

$GILD 2016 net product sales guidance $30-31B versus actual 2015 net product sales $32.2B

— Adam Feuerstein (@adamfeuerstein) February 2, 2016

The only good news I had in 2016.

When your daughter receives a letter saying she was accepted to college. pic.twitter.com/uXKeOG6ViK

— Adam Feuerstein (@adamfeuerstein) February 18, 2016

Brief tenure?

Dr. Robert Califf, the new FDA commissioner.

— Adam Feuerstein (@adamfeuerstein) February 24, 2016

We were so hopeful, but we're still waiting... 

Yeezus on $GILD M&A coming out of his conference y'day: pic.twitter.com/m7M1xmT2Ax

— Adam Feuerstein (@adamfeuerstein) February 25, 2016

Taking out the trash.

This list... Updated

1. $HEB fires Bill Carter
2. $GALE lawsuit settlement
3. $CTIC NDA withdrawal
4. $CPRX $PTCT RTF letters
5. $PPHM fail

— Adam Feuerstein (@adamfeuerstein) February 25, 2016

Obituary.

Al Mann, 90, is dead. $MNKD was an anomaly in a hugely successful career as businessman, generous philanthropist. Peace to his family.

— Adam Feuerstein (@adamfeuerstein) February 26, 2016

My new best friend.

Big news! Meet new member of my family. Just adopted. We'll be picking up this cutie this wknd or next. Dog ❤️!! pic.twitter.com/2FRwUSh2wP

— Adam Feuerstein (@adamfeuerstein) February 29, 2016

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind